Department of Health Science, University of Kochi, Kochi 781-8515, Japan.
Clin Biochem. 2012 Sep;45(13-14):1086-91. doi: 10.1016/j.clinbiochem.2012.05.027. Epub 2012 Jun 2.
We developed an ultrasensitive enzyme immunoassay (ICT-EIA) for insulin autoantibody (IAA) measurements to better understand the pathophysiology of diabetes.
We developed ICT-EIA for IAA and measured IAA in 24 patients with type 1 diabetes, 30 patients with type 2 diabetes, 30 patients with methimazole-treated Graves' disease, 20 patients with Hashimoto's disease, 9 patients with hyperinsulinemia, and 73 healthy control subjects.
The conventional ELISA identified 3 patients with type 1 diabetes and 2 patients with type 2 diabetes as IAA positive, whereas 15 patients with type 1 diabetes, 7 patients with type 2 diabetes, and 4 patients with methimazole-treated Graves' disease were identified as IAA positive using ICT-EIA.
The ICT-EIA is an ultrasensitive and specific assay for IAA, and its use may provide a better understanding of the role of IAA in diabetes onset and progression.
我们开发了一种用于胰岛素自身抗体（IAA）测量的超敏酶免疫分析（ICT-EIA），以更好地了解糖尿病的病理生理学。
我们开发了用于 IAA 的 ICT-EIA，并测量了 24 名 1 型糖尿病患者、30 名 2 型糖尿病患者、30 名甲巯咪唑治疗的格雷夫斯病患者、20 名桥本甲状腺炎患者、9 名高胰岛素血症患者和 73 名健康对照者的 IAA。
传统 ELISA 鉴定出 3 名 1 型糖尿病患者和 2 名 2 型糖尿病患者为 IAA 阳性，而使用 ICT-EIA 鉴定出 15 名 1 型糖尿病患者、7 名 2 型糖尿病患者和 4 名甲巯咪唑治疗的格雷夫斯病患者为 IAA 阳性。
ICT-EIA 是一种超敏和特异的 IAA 检测方法，其使用可能有助于更好地了解 IAA 在糖尿病发病和进展中的作用。
